CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 924 enrolled
Drug / intervention
desvenlafaxine succinate sustained-release 50 mg/day +2 moredrug
Likely dose
desvenlafaxine succinate sustained-release 50 mg/dayfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01432457
NCT01432457Phase 4Completed
CompareCT.gov

A Phase IV, Multicenter, Randomized, 8-Week, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy of 2 Fixed Doses (50 and 100 mg/Day) of Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder

Pfizer·interventional·Posted Sep 13, 2011·Updated Jan 20, 2014

In Brief

A Phase 4 clinical trial evaluating desvenlafaxine succinate sustained-release 50 mg/day, desvenlafaxine succinate sustained-release 100 mg/day, and 1 other intervention for Major Depressive Disorder. Completed, enrolled 924 participants across 61 sites.

Detailed Summary

A multicenter, 8-week study to evaluate the efficacy of 2 doses (50 and 100 mg/day) of desvenlafaxine succinate sustained-release (DVS SR) versus placebo in adult outpatients with major depressive disorder.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMajor Depressive Disorder
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedSep 13, 2011
Enrollment StartOct 1, 2011
Primary CompletionJul 1, 2012
Study CompletionAug 1, 2012
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 14.8 years ago

Interventions

desvenlafaxine succinate sustained-release 50 mg/daydrug

50 mg tablets of DVS SR taken orally once daily for 8 weeks; 1 week of placebo taper

desvenlafaxine succinate sustained-release 100 mg/daydrug

100 mg tablets of DVS SR taken orally once daily for 8 weeks (which includes 1 week of titration at 50 mg/day); 1 week of taper at 50 mg/day

placebodrug

50 mg and 100 mg placebo matching tablets taken orally once daily for 8 weeks; 1 week of placebo taper